HLA-A/F/H抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P06699(HLA-A/F/H Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P06699(HLA-A/F/H Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

HLA-A/F/H antibodies target specific human leukocyte antigen (HLA) class I molecules critical in immune regulation. HLA class I molecules, including HLA-A, -B, -C (classical), and non-classical HLA-F/-G/-E, are cell-surface glycoproteins that present endogenous antigens to CD8+ T cells. HLA-A is a classical HLA-I molecule with high polymorphism, playing a central role in transplant compatibility and antiviral immunity. HLA-F, a non-classical molecule, is expressed in immune-privileged tissues and regulates natural killer (NK) cell activity by interacting with NK cell receptors. HLA-H, though less characterized, is sometimes referenced in older literature as a non-classical HLA variant, though this designation remains ambiguous due to nomenclature overlaps (e.g., HLA-H may refer to HLA-G pseudogenes or typing errors).

Antibodies against HLA-A/F/H are clinically significant. HLA-A antibodies are commonly implicated in transplant rejection and platelet transfusion refractoriness. HLA-F antibodies, though less studied, may influence pregnancy complications (e.g., preeclampsia) or tumor immune evasion. HLA-H-related antibodies, if confirmed, could have niche roles in autoimmune or inflammatory conditions. Detection methods like Luminex-based assays are used to identify these antibodies, guiding donor selection in transplantation or assessing immune dysregulation risks. Research continues to clarify their precise pathogenic mechanisms and therapeutic targeting potential.